Cargando…

Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran

Background and Purpose  Accurate and rapid assessment of coagulation status is necessary to guide thrombolysis or reversal of anticoagulation in stroke patients, but commercially available point-of-care (POC) assays are not suited for coagulation testing in patients treated with direct oral anticoag...

Descripción completa

Detalles Bibliográficos
Autores principales: Härtig, Florian, Birschmann, Ingvild, Peter, Andreas, Ebner, Matthias, Spencer, Charlotte, Gramlich, Michael, Richter, Hardy, Kuhn, Joachim, Lehmann, Rainer, Blumenstock, Gunnar, Zuern, Christine S., Ziemann, Ulf, Poli, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180376/
https://www.ncbi.nlm.nih.gov/pubmed/33469905
http://dx.doi.org/10.1055/s-0040-1721775
_version_ 1783703990091907072
author Härtig, Florian
Birschmann, Ingvild
Peter, Andreas
Ebner, Matthias
Spencer, Charlotte
Gramlich, Michael
Richter, Hardy
Kuhn, Joachim
Lehmann, Rainer
Blumenstock, Gunnar
Zuern, Christine S.
Ziemann, Ulf
Poli, Sven
author_facet Härtig, Florian
Birschmann, Ingvild
Peter, Andreas
Ebner, Matthias
Spencer, Charlotte
Gramlich, Michael
Richter, Hardy
Kuhn, Joachim
Lehmann, Rainer
Blumenstock, Gunnar
Zuern, Christine S.
Ziemann, Ulf
Poli, Sven
author_sort Härtig, Florian
collection PubMed
description Background and Purpose  Accurate and rapid assessment of coagulation status is necessary to guide thrombolysis or reversal of anticoagulation in stroke patients, but commercially available point-of-care (POC) assays are not suited for coagulation testing in patients treated with direct oral anticoagulants (DOACs). We aimed to evaluate the direct thrombin monitoring (DTM) test card by Helena Laboratories (Texas, United States) for anti-IIa-specific POC coagulation testing, hypothesizing that its POC-ecarin clotting time (POC-ECT) accurately reflects dabigatran plasma concentrations. Methods  A prospective single-center diagnostic study (ClinicalTrials.gov-identifier: NCT02825394) was conducted enrolling patients receiving a first dose of dabigatran and patients already on dabigatran treatment. Blood samples were collected before drug intake and 0.5, 1, 2, 8, and 12 hours after intake. POC-ECT was performed using whole blood (WB), citrated blood (CB), and citrated plasma (CP). Dabigatran plasma concentrations were determined by mass spectrometry. Results  In total, 240 blood samples from 40 patients contained 0 to 275 ng/mL of dabigatran. POC-ECT with WB/CB/CP ranged from 20 to 186/184/316 seconds. Pearson's correlation coefficient showed a strong correlation between dabigatran concentrations and POC-ECT with WB/CB/CP ( R (2)  = 0.78/0.90/0.92). Dabigatran concentrations >30 and >50 ng/mL (thresholds for thrombolysis, surgery, and reversal therapy according to clinical guidelines) were detected by POC-ECT with WB/CB/CP (>36/35/45 and >43/45/59 seconds) with 95/97/97 and 96/98/97% sensitivity, and 81/87/94 and 74/60/91% specificity. Conclusion  This first study evaluating DOAC-specific POC coagulation testing revealed an excellent correlation of POC-ECT with actual dabigatran concentrations. Detecting clinically relevant dabigatran levels with high sensitivity/specificity, the DTM assay represents a suitable diagnostic tool in acute stroke, hemorrhage, and urgent surgery.
format Online
Article
Text
id pubmed-8180376
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-81803762021-06-08 Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran Härtig, Florian Birschmann, Ingvild Peter, Andreas Ebner, Matthias Spencer, Charlotte Gramlich, Michael Richter, Hardy Kuhn, Joachim Lehmann, Rainer Blumenstock, Gunnar Zuern, Christine S. Ziemann, Ulf Poli, Sven Thromb Haemost Background and Purpose  Accurate and rapid assessment of coagulation status is necessary to guide thrombolysis or reversal of anticoagulation in stroke patients, but commercially available point-of-care (POC) assays are not suited for coagulation testing in patients treated with direct oral anticoagulants (DOACs). We aimed to evaluate the direct thrombin monitoring (DTM) test card by Helena Laboratories (Texas, United States) for anti-IIa-specific POC coagulation testing, hypothesizing that its POC-ecarin clotting time (POC-ECT) accurately reflects dabigatran plasma concentrations. Methods  A prospective single-center diagnostic study (ClinicalTrials.gov-identifier: NCT02825394) was conducted enrolling patients receiving a first dose of dabigatran and patients already on dabigatran treatment. Blood samples were collected before drug intake and 0.5, 1, 2, 8, and 12 hours after intake. POC-ECT was performed using whole blood (WB), citrated blood (CB), and citrated plasma (CP). Dabigatran plasma concentrations were determined by mass spectrometry. Results  In total, 240 blood samples from 40 patients contained 0 to 275 ng/mL of dabigatran. POC-ECT with WB/CB/CP ranged from 20 to 186/184/316 seconds. Pearson's correlation coefficient showed a strong correlation between dabigatran concentrations and POC-ECT with WB/CB/CP ( R (2)  = 0.78/0.90/0.92). Dabigatran concentrations >30 and >50 ng/mL (thresholds for thrombolysis, surgery, and reversal therapy according to clinical guidelines) were detected by POC-ECT with WB/CB/CP (>36/35/45 and >43/45/59 seconds) with 95/97/97 and 96/98/97% sensitivity, and 81/87/94 and 74/60/91% specificity. Conclusion  This first study evaluating DOAC-specific POC coagulation testing revealed an excellent correlation of POC-ECT with actual dabigatran concentrations. Detecting clinically relevant dabigatran levels with high sensitivity/specificity, the DTM assay represents a suitable diagnostic tool in acute stroke, hemorrhage, and urgent surgery. Georg Thieme Verlag KG 2021-06 2021-01-14 /pmc/articles/PMC8180376/ /pubmed/33469905 http://dx.doi.org/10.1055/s-0040-1721775 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Härtig, Florian
Birschmann, Ingvild
Peter, Andreas
Ebner, Matthias
Spencer, Charlotte
Gramlich, Michael
Richter, Hardy
Kuhn, Joachim
Lehmann, Rainer
Blumenstock, Gunnar
Zuern, Christine S.
Ziemann, Ulf
Poli, Sven
Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran
title Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran
title_full Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran
title_fullStr Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran
title_full_unstemmed Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran
title_short Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran
title_sort specific point-of-care testing of coagulation in patients treated with dabigatran
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180376/
https://www.ncbi.nlm.nih.gov/pubmed/33469905
http://dx.doi.org/10.1055/s-0040-1721775
work_keys_str_mv AT hartigflorian specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran
AT birschmanningvild specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran
AT peterandreas specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran
AT ebnermatthias specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran
AT spencercharlotte specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran
AT gramlichmichael specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran
AT richterhardy specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran
AT kuhnjoachim specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran
AT lehmannrainer specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran
AT blumenstockgunnar specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran
AT zuernchristines specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran
AT ziemannulf specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran
AT polisven specificpointofcaretestingofcoagulationinpatientstreatedwithdabigatran